A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome
Identifieur interne : 003270 ( Main/Curation ); précédent : 003269; suivant : 003271A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome
Auteurs : Andrew D. Krahn [Canada] ; George J. Klein [Canada] ; Raymond Yee [Canada]Source :
- Pacing and Clinical Electrophysiology [ 0147-8389 ] ; 2001-08.
English descriptors
- KwdEn :
- Adolescent, Adult, Anti-Arrhythmia Agents (administration & dosage), Anti-Arrhythmia Agents (therapeutic use), Atrial Fibrillation (drug therapy), Atrial Fibrillation (etiology), Double-Blind Method, Electrophysiologic Techniques, Cardiac, Humans, Infusions, Intravenous, Male, Middle Aged, Phenethylamines (administration & dosage), Phenethylamines (therapeutic use), Pilot Projects, Sulfonamides (administration & dosage), Sulfonamides (therapeutic use), Tachycardia, Atrioventricular Nodal Reentry (drug therapy), Tachycardia, Atrioventricular Nodal Reentry (etiology), Wolff-Parkinson-White Syndrome (complications), Wolff-Parkinson-White Syndrome (drug therapy), atrial fibrillation, dofetilide, supraventricular tachycardia, wolff‐parkinson‐white syndrome.
- MESH :
- chemical , administration & dosage : Anti-Arrhythmia Agents, Phenethylamines, Sulfonamides.
- chemical , therapeutic use : Anti-Arrhythmia Agents, Phenethylamines, Sulfonamides.
- complications : Wolff-Parkinson-White Syndrome.
- drug therapy : Atrial Fibrillation, Tachycardia, Atrioventricular Nodal Reentry, Wolff-Parkinson-White Syndrome.
- etiology : Atrial Fibrillation, Tachycardia, Atrioventricular Nodal Reentry.
- Adolescent, Adult, Double-Blind Method, Electrophysiologic Techniques, Cardiac, Humans, Infusions, Intravenous, Male, Middle Aged, Pilot Projects.
Abstract
KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.
Url:
DOI: 10.1046/j.1460-9592.2001.01258.x
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000137
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000137
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001099
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003752
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001560
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001560
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001560
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000177
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000177
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000177
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003602
Links to Exploration step
ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title>
<author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1046/j.1460-9592.2001.01258.x</idno>
<idno type="url">https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000137</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000137</idno>
<idno type="wicri:Area/Istex/Curation">000137</idno>
<idno type="wicri:Area/Istex/Checkpoint">001099</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001099</idno>
<idno type="wicri:doubleKey">0147-8389:2001:Krahn A:a:randomized:double</idno>
<idno type="wicri:Area/Main/Merge">003752</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11523612</idno>
<idno type="wicri:Area/PubMed/Corpus">001560</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001560</idno>
<idno type="wicri:Area/PubMed/Curation">001560</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001560</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001560</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001560</idno>
<idno type="wicri:Area/Ncbi/Merge">000177</idno>
<idno type="wicri:Area/Ncbi/Curation">000177</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000177</idno>
<idno type="wicri:doubleKey">0147-8389:2001:Krahn A:a:randomized:double</idno>
<idno type="wicri:Area/Main/Merge">003602</idno>
<idno type="wicri:Area/Main/Curation">003270</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title>
<author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Pacing and Clinical Electrophysiology</title>
<idno type="ISSN">0147-8389</idno>
<idno type="eISSN">1540-8159</idno>
<imprint><publisher>Blackwell Futura Publishing, Inc.</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2001-08">2001-08</date>
<biblScope unit="volume">24</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1258">1258</biblScope>
<biblScope unit="page" to="1260">1260</biblScope>
</imprint>
<idno type="ISSN">0147-8389</idno>
</series>
<idno type="istex">118ADF7F2B55924522341A65CD078ED7E7AA300A</idno>
<idno type="DOI">10.1046/j.1460-9592.2001.01258.x</idno>
<idno type="ArticleID">PACE1258</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0147-8389</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Anti-Arrhythmia Agents (administration & dosage)</term>
<term>Anti-Arrhythmia Agents (therapeutic use)</term>
<term>Atrial Fibrillation (drug therapy)</term>
<term>Atrial Fibrillation (etiology)</term>
<term>Double-Blind Method</term>
<term>Electrophysiologic Techniques, Cardiac</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Phenethylamines (administration & dosage)</term>
<term>Phenethylamines (therapeutic use)</term>
<term>Pilot Projects</term>
<term>Sulfonamides (administration & dosage)</term>
<term>Sulfonamides (therapeutic use)</term>
<term>Tachycardia, Atrioventricular Nodal Reentry (drug therapy)</term>
<term>Tachycardia, Atrioventricular Nodal Reentry (etiology)</term>
<term>Wolff-Parkinson-White Syndrome (complications)</term>
<term>Wolff-Parkinson-White Syndrome (drug therapy)</term>
<term>atrial fibrillation</term>
<term>dofetilide</term>
<term>supraventricular tachycardia</term>
<term>wolff‐parkinson‐white syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Arrhythmia Agents</term>
<term>Phenethylamines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Arrhythmia Agents</term>
<term>Phenethylamines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Tachycardia, Atrioventricular Nodal Reentry</term>
<term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Tachycardia, Atrioventricular Nodal Reentry</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Electrophysiologic Techniques, Cardiac</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</div>
</front>
</TEI>
<double idat="0147-8389:2001:Krahn A:a:randomized:double"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title>
<author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1046/j.1460-9592.2001.01258.x</idno>
<idno type="url">https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000137</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000137</idno>
<idno type="wicri:Area/Istex/Curation">000137</idno>
<idno type="wicri:Area/Istex/Checkpoint">001099</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001099</idno>
<idno type="wicri:doubleKey">0147-8389:2001:Krahn A:a:randomized:double</idno>
<idno type="wicri:Area/Main/Merge">003752</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title>
<author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Pacing and Clinical Electrophysiology</title>
<idno type="ISSN">0147-8389</idno>
<idno type="eISSN">1540-8159</idno>
<imprint><publisher>Blackwell Futura Publishing, Inc.</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2001-08">2001-08</date>
<biblScope unit="volume">24</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1258">1258</biblScope>
<biblScope unit="page" to="1260">1260</biblScope>
</imprint>
<idno type="ISSN">0147-8389</idno>
</series>
<idno type="istex">118ADF7F2B55924522341A65CD078ED7E7AA300A</idno>
<idno type="DOI">10.1046/j.1460-9592.2001.01258.x</idno>
<idno type="ArticleID">PACE1258</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0147-8389</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>atrial fibrillation</term>
<term>dofetilide</term>
<term>supraventricular tachycardia</term>
<term>wolff‐parkinson‐white syndrome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.</title>
<author><name sortKey="Krahn, A D" sort="Krahn, A D" uniqKey="Krahn A" first="A D" last="Krahn">A D Krahn</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Cardiology, University of Western Ontario, London, Canada. akrahn@julian.uwo.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name>
</author>
<author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11523612</idno>
<idno type="pmid">11523612</idno>
<idno type="wicri:Area/PubMed/Corpus">001560</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001560</idno>
<idno type="wicri:Area/PubMed/Curation">001560</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001560</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001560</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001560</idno>
<idno type="wicri:Area/Ncbi/Merge">000177</idno>
<idno type="wicri:Area/Ncbi/Curation">000177</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000177</idno>
<idno type="wicri:doubleKey">0147-8389:2001:Krahn A:a:randomized:double</idno>
<idno type="wicri:Area/Main/Merge">003602</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.</title>
<author><name sortKey="Krahn, A D" sort="Krahn, A D" uniqKey="Krahn A" first="A D" last="Krahn">A D Krahn</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Cardiology, University of Western Ontario, London, Canada. akrahn@julian.uwo.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name>
</author>
<author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name>
</author>
</analytic>
<series><title level="j">Pacing and clinical electrophysiology : PACE</title>
<idno type="ISSN">0147-8389</idno>
<imprint><date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Anti-Arrhythmia Agents (administration & dosage)</term>
<term>Anti-Arrhythmia Agents (therapeutic use)</term>
<term>Atrial Fibrillation (drug therapy)</term>
<term>Atrial Fibrillation (etiology)</term>
<term>Double-Blind Method</term>
<term>Electrophysiologic Techniques, Cardiac</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Phenethylamines (administration & dosage)</term>
<term>Phenethylamines (therapeutic use)</term>
<term>Pilot Projects</term>
<term>Sulfonamides (administration & dosage)</term>
<term>Sulfonamides (therapeutic use)</term>
<term>Tachycardia, Atrioventricular Nodal Reentry (drug therapy)</term>
<term>Tachycardia, Atrioventricular Nodal Reentry (etiology)</term>
<term>Wolff-Parkinson-White Syndrome (complications)</term>
<term>Wolff-Parkinson-White Syndrome (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Arrhythmia Agents</term>
<term>Phenethylamines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Arrhythmia Agents</term>
<term>Phenethylamines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Tachycardia, Atrioventricular Nodal Reentry</term>
<term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Tachycardia, Atrioventricular Nodal Reentry</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Electrophysiologic Techniques, Cardiac</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pharmacological conversion of arrhythmias in Wolff-Parkinson-White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18-63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo-controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003270 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003270 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A |texte= A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome }}
This area was generated with Dilib version V0.6.29. |